
Washington State University: Link to full article (WSU News) A quick, affordable diagnostic test developed by a Washington State University researcher may help curb one

Halifax, Nova Scotia, 14 March, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory approval in Canada

Halifax, Nova Scotia, 11 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™ CoV2Flu Antigen

Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens Rebecca Rossetti1, Tara

Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent,

Halifax, Nova Scotia, 29 December, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) presents its latest addition to the VYRA™ product line, the VYRA™ TriDemic

A study completed by the Indian Red Cross Blood Society showed that MedMira’s Multiplo® TP/HIV Rapid Test is your immediate quality answer. MedMira’s Multiplo® TP/HIV

Halifax, Nova Scotia, 14 October, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen
Contacts Investor Relations
For more information about MedMira or inquiries related to Investor Relations, please contact us. Our Investor relations team will get back to you immediately.
Corporate Headquarters
155 Chain Lake Drive, Suite 1
Halifax, Nova Scotia B3S 1B3
Canada
Phone: 902 450 1588
T/F. 877 633 6372
E-Mail: ir@medmira.com